Lisa Gallicchio1, Shahinaz M Gadalla2, John D Murphy1, Naoko I Simonds3. 1. Epidemiology and Genomics Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville. 2. Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville. 3. Scientific Consulting Group, Inc., Gaithersburg.
Abstract
Background: It has been hypothesized that cancer treatments cause accelerated aging through a mechanism involving the shortening of telomeres. However, the effect of cancer treatments on telomere length is unclear. Methods: We systematically reviewed the epidemiological evidence evaluating the associations between cancer treatment and changes in telomere length. Searches were performed in PubMed for the period of January 1966 through November 2016 using the following search strategy: telomere AND (cancer OR tumor OR carcinoma OR neoplasm) AND (survivor OR patient). Data were extracted and the quality of studies was assessed. Results: A total of 25 studies were included in this review. Ten were solid cancer studies, 11 were hematological malignancy studies, and 4 included a mixed sample of both solid and hematological cancers. Three of the 10 solid tumor studies reported a statistically significant association between cancer treatment and telomere length shortening, and one reported longer telomere length after treatment. Among the hematological cancer studies, three showed statistically significant decreases in telomere length with treatment, and two showed elongation. When these studies were rated using quality criteria, most of the studies were judged to be of moderate quality. Conclusions: The findings from this review indicate that the effect of cancer treatment on telomere length may differ by cancer type and treatment as well as other factors. Definitive conclusions cannot be made based on the published literature, because sample sizes tended to be small; treatments, cancer types, and biospecimens were heterogenous; and the length of follow-up times differed greatly.
Background: It has been hypothesized that cancer treatments cause accelerated aging through a mechanism involving the shortening of telomeres. However, the effect of cancer treatments on telomere length is unclear. Methods: We systematically reviewed the epidemiological evidence evaluating the associations between cancer treatment and changes in telomere length. Searches were performed in PubMed for the period of January 1966 through November 2016 using the following search strategy: telomere AND (cancer OR tumor OR carcinoma OR neoplasm) AND (survivor OR patient). Data were extracted and the quality of studies was assessed. Results: A total of 25 studies were included in this review. Ten were solid cancer studies, 11 were hematological malignancy studies, and 4 included a mixed sample of both solid and hematological cancers. Three of the 10 solid tumor studies reported a statistically significant association between cancer treatment and telomere length shortening, and one reported longer telomere length after treatment. Among the hematological cancer studies, three showed statistically significant decreases in telomere length with treatment, and two showed elongation. When these studies were rated using quality criteria, most of the studies were judged to be of moderate quality. Conclusions: The findings from this review indicate that the effect of cancer treatment on telomere length may differ by cancer type and treatment as well as other factors. Definitive conclusions cannot be made based on the published literature, because sample sizes tended to be small; treatments, cancer types, and biospecimens were heterogenous; and the length of follow-up times differed greatly.
Authors: Hanna K Sanoff; Allison M Deal; Janakiraman Krishnamurthy; Chad Torrice; Patrick Dillon; Jessica Sorrentino; Joseph G Ibrahim; Trevor A Jolly; Grant Williams; Lisa A Carey; Amy Drobish; Brittaney-Belle Gordon; Shani Alston; Arti Hurria; Karin Kleinhans; K Lenhard Rudolph; Norman E Sharpless; Hyman B Muss Journal: J Natl Cancer Inst Date: 2014-03-28 Impact factor: 13.506
Authors: Brian L Pipes; Tom Tsang; Shu-Xin Peng; Roger Fiederlein; Michael Graham; David T Harris Journal: Transfusion Date: 2006-06 Impact factor: 3.157
Authors: M Ruella; A Rocci; I Ricca; C Carniti; C Labetti Bodoni; M Ladetto; D Caracciolo; M Boccadoro; C Carlo-Stella; P Corradini; C Tarella Journal: Bone Marrow Transplant Date: 2009-10-19 Impact factor: 5.483
Authors: C P Schröder; G B Wisman; S de Jong; W T van der Graaf; M H Ruiters; N H Mulder; L F de Leij; A G van der Zee; E G de Vries Journal: Br J Cancer Date: 2001-05-18 Impact factor: 7.640
Authors: Tsz-Kwong Man; Geraldine Aubert; Melissa A Richard; Wanda LeJeune; Elmira Hariri; Tatiana Goltsova; Amos Gaikwad; Yan Chen; Jillian Whitton; Wendy M Leisenring; Michael A Arnold; Joseph P Neglia; Yutaka Yasui; Leslie L Robison; Gregory T Armstrong; Smita Bhatia; Maria M Gramatges Journal: Cancer Epidemiol Biomarkers Prev Date: 2021-11-15 Impact factor: 4.090
Authors: Kirsten K Ness; Zhaoming Wang; Nan Song; Zhenghong Li; Na Qin; Carrie R Howell; Carmen L Wilson; John Easton; Heather L Mulder; Michael N Edmonson; Michael C Rusch; Jinghui Zhang; Melissa M Hudson; Yutaka Yasui; Leslie L Robison Journal: Clin Cancer Res Date: 2020-01-22 Impact factor: 12.531
Authors: Areej A Alhareeri; Kellie J Archer; Han Fu; Debra E Lyon; R K Elswick; Debra L Kelly; Angela R Starkweather; Lynne W Elmore; Yahya A Bokhari; Colleen K Jackson-Cook Journal: Breast Cancer Res Date: 2020-12-04 Impact factor: 6.466
Authors: Kristyna Tomasova; Michal Kroupa; Alzbeta Zinkova; Marie Korabecna; Veronika Vymetalkova; Pavel Skrobanek; Ladislav Sojka; Miroslav Levy; Kari Hemminki; Vaclav Liska; Petr Hosek; Rajiv Kumar; Ludmila Vodickova; Pavel Vodicka Journal: Front Oncol Date: 2022-09-20 Impact factor: 5.738